Embolization in Hereditary Coagulopathies

Launched by UNIVERSITY OF SAO PAULO GENERAL HOSPITAL · Nov 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with hereditary coagulopathies, such as hemophilia, who also suffer from joint problems due to bleeding in the joints (called hemarthrosis) and inflammation (synovitis). The trial aims to see how effective a procedure called superselective embolization is in reducing symptoms and improving quality of life for these patients. Participants will undergo various assessments, including imaging tests like X-rays and MRIs, as well as evaluations of pain, joint function, and overall well-being over a period of five years.

To be eligible for this study, patients must have hereditary coagulopathies and joint issues confirmed by imaging tests. The trial is open to individuals of all ages and genders who are willing to participate and complete the required assessments. Throughout the study, participants will receive close follow-up care at the Hemophilia Center and can expect to have their health closely monitored, helping researchers understand how this treatment impacts their daily lives over time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with hereditary coagulopathies with arthropathy (i.e., chronic synovitis due to hemarthrosis), with X-ray and MRI (documenting synovitis) followed up at the Hemophilia Center HC-FMUSP.
• Exclusion Criteria:
• • Patients who do not complete the planned assessments
• • Patients who do not accept to continue with the study.